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ABSTRACT 
THE SECOND GENERATION PROTEASOME INHIBITOR CARFILZOMIB 
INTERACTS SYNERGISTICALLY WITH HDAC INHIBITORS IN DIFFUSE 
LARGE B-CELL LYMPHOMA CELLS THROUGH MULTIPLE MECHANISMS 
AND CIRCUMVENTS BORTEZOMIB RESISTANCE 
 
By Dmitry Lembersky, Bachelor of Science 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Dr. Steven Grant, MD 
Department of Biochemistry 
 
Mechanisms underlying the interactions between the proteasome inhibitor carfilzomib 
and HDAC inhibitors were examined in both germinal center (GC) and activated B-cell 
(ABC) subtypes of human diffuse large B-cell lymphoma (DLBCL).  Simultaneous 
exposure to minimally toxic concentrations of carfilzomib and HDAC inhibitor vorinostat 
resulted in the release of mitochondrial pro-apoptotic proteins SMAC and cytochrome c, 
pro-apoptotic caspase activation, and synergistic induction in apoptosis in both ABC and 
GC DLBCL subtypes.  These events were associated with a marked increase in the stress 
kinase JNK, ROS generation, G2-M cell cycle arrest, as well as induction of DNA 
damage. Genetic knockdown of JNK resulted in a significant decrease in 
carfilzomib/vorinostat induced cell death.  Co-administration of the antioxidant MnTBAP 
significantly reduced carfilzomib/vorinostat induced cell death, and resulted in a marked 
decrease in caspase-3 as well as a striking decrease in JNK phosphorylation.  Tumor 
 viii 
growth reduction was also observed in animal models that were treated with a combined 
regimen of carfilzomib and vorinostat.  Finally, the combined treatment of 
carfilzomib/vorinostat was able to overcome any cross-resistance to carfIlzomib in 
bortezomib resistant cells.  Collectively, these finding indicate that the combined regimen 
of carfilzomib and HDAC inhibitors promote lethality in ABC and GC human DLBCL 
cells by a variety of mechanisms both in vitro and in vivo. Further studies are necessary 
for clinical development of this drug regimen.  
 
 
 
 
 
 
 
 
 
 
 
 
 1 
INTRODUCTION 
 
LYMPHOMA 
The groups of cancers under the general term lymphoma are very broad, and 
symbolize the disease of the impaired immune system. This includes lymphomas of B-
cell origin, T-cell origin, and natural killer cell origin. Lymphomas are broadly classified 
into two major groups i.e. Hodgkins (HL) and Non-Hodgkin lymphoma (NHL). The 
classifications are based on the differences in characteristics, morphology of the 
cancerous cells and prognosis with current therapy.   
Diffuse lymphocytic B-cell lymphoma (DLBCL) is the most frequently 
encountered lymphoma in adults, accounting for 30-40% of adult neoplasms (1).  It is an 
aggressive malignancy of mature B lymphocytes, with 25,000 new cases annually, 
accounting for roughly 40% of cases of non-Hodgkin's lymphoma. Patients with DLBCL 
have highly variable clinical outcomes; although most patients respond initially to 
chemotherapy, fewer than half of the patients achieve a durable remission (2). Although 
treatment progress, including the development of chemotherapeutic regimens such as R-
CHOP or advances in bone marrow transplantation have led to an improved prognosis 
(3), many patients become resistant to standard therapy and succumb to their disease. 
Consequently, novel treatment approaches continue to be sought.  
Recently, microarray analyses performed on untreated DLBCL has lead to the 
identification of two main sub-types, germinal center (GC-DLBCL), and activated B-cell 
(ABC-DLBCL).  Both have a distinct gene expression profile, characteristic of either 
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normal germinal center b-cells or activated blood memory b-cells (4).  The germinal 
center-like subgroup is correlated with a significantly better prognosis in comparison 
with the activated b-cell like subgroup (4), and the 5-year survival rate of both is 59% 
and 30% respectively (5).  A third subgroup is comprised of cases that do not express the 
genetic profile of wither the ABC or GC subgroups, yet has a poor prognosis similar to 
that of the ABC subgroup (4).  Different oncogenic mechanisms underlie both the ABC 
and GC subgroups, with Bcl2 gene rearrangement occurring almost exclusively with the 
GC subgroup (4,6-8), while NF-κB signaling activation occurs in the ABC subgroup (4).  
Such findings raise the possibility that novel therapies may ultimately be targeted to 
specific DLBCL sub-types (5,6).   
 
The PROTEASOME 
The two main routes of protein degradation are proteasomes and lysosomes.  
While lysosomes degrade extracellular and transmembrane proteins, proteasomes 
primarily degrade intracellular proteins.  This could be due to phosphorylation by 
signaling pathways, or they could be recognized as being misfolded.  The proteins are 
tagged for degradation via an ubiquitin tag (9).   
The functionally active 26S proteasomes is an ATP-dependent proteolytic 
complex, located in the cytoplasm and nucleus of eukaryotic cells.  It is made up of a 20S 
core catalytic subunit, capped by both ends by 19S regulatory subunits (9,10).  Generally, 
the proteasome identifies proteins destined for degradation by their ubiquitin tag, 
although ubiquitination is not always necessary for degradation of every protein (9). 
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The 20S proteasome subunit is a cylindrical structure composed of 28 protein 
subunits, organized into 4 stacked rings.  The top and bottom rings are formed by 7 
polypeptides, termed α-subunits, and the two inner rings are made up of 7 β-subunits.  
The β-subunits contain the enzymatically active sites of the proteasome (9).  The β1, β2, 
and β5 subunits are characterized as chymotryptic-like, tryptic-like, and post-glutamyl 
peptidyl hydrolytic-like (9,11-13). 
The 19S regulatory complex contains 20 subunits which bind to both ends of the 
20S proteasomes to form the 26S proteasomes (9).  ATP hydrolysis is required for both 
the formation of the 26S complex and for unfolding proteins for entry into the catalytic 
core of the proteasomes (9,12,14).  It is therefore possible that the increasing protein 
Reproduced from Adams J, 2004 
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degradation requirements in rapidly proliferating cancer cells make them more 
susceptible to proteasomal inhibition (15).   
Targeting the majority of proteins to the proteasome for degradation requires 
polyubiquitination, but it can also serve as a signal for trafficking, kinase activation, and 
other nonproteolytic activities (9,16).  Conjugation of ubiquitin to a target protein 
proceeds in via a three-step mechanism.  Initially, ubiquitin is activated in its C-terminal 
glycine by the ubiquitin-activating enzyme, E1.  Following activation, one of several E2 
enzymes (ubiquitin-conjugating enzymes) transfers ubiquitin from E1 to a member of the 
ubiquitin-protein ligase family, E3, to which the substrate protein is specifically bound. 
This enzyme catalyzes the last step in the conjugation process, covalent attachment of 
ubiquitin to the substrate (11).  Ubiquitination is not absolutely required for proteasomal 
degradation however, as the tumor suppressor RB family proteins can undergo 
proteasomal degradation through a ubiquitin-independent pathway.    
    
ER STRESS AND THE UNFOLDED PROTEIN RESPONSE 
 An excessive accumulation of misfolded proteins within the ER-Golgi network 
elicits a cellular response which initially promotes cell survival, but will lead to apoptosis 
if the repair mechanisms are overwhelmed (15).  The core of this defense system is 
known as the unfolded protein response (15,17), which functions to increase expression 
of protein chaperones such as Grp78/BiP, in order to limit protein aggregation, to 
increase biosynthesis of structural components of the ER, and to inhibit overall protein 
synthesis so that the load on the ER-Golgi network is reduced. Upstream control of the 
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unfolded protein response is mediated via activation of three ER transmembrane proteins, 
the serine/threonine kinase PERK, IRE and the bZIP transcription factor, ATF6 
(15,17,18).    
 
 
The unfolded protein response (UPR). In response to a build-up of misfolded proteins 
within the endoplasmic reticulum (ER), the molecular chaperone glucose regulated 
protein-78 kD (Grp78, commonly known as BiP) dissociates from the luminal domains of 
PKR-like ER kinase (PERK), IRE1, and ATF6, resulting in their activation. PERK-
mediated phosphorylation of eIF2α coordinates activation of the transcription factor 
ATF4 with attenuation of global protein synthesis and activation of autophagy.  
Reproduced from McConkey DJ, et al, 2008. 
 
It is unknown exactly how proteins are shuttled to the proteasome for degradation, but 
current evidence points to discrete structures known as aggresomes (15,19-21), as well as 
the cytosolic chaparone, HSP70 (15,22).  The activity of proteasome inhibitors may be 
improved by blocking proteasome inhibitor-induced aggresome formation with pan-
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specific chemical HDAC inhibitors such as trichostatin A or vorinostat (SAHA) 
(15,23,24).  It has been shown that chemical pan HDAC inhibitors are some of the most 
potent PI-sensitizing agents, capable of restoring PI sensitivity in cells that are 
completely resistant to the agents basally (15,24).      
 
EFFECT OF PROTEASOME FUNCTIONS ON SIGNALLING 
 It is known that many proteasome substrates are mediators of pathways which are 
disregulated in cancers (9), in addition 
to it’s conventional role of inhibition of 
proteasome synthesis. It is reported that 
proteasome inhibitors modulate targets 
which govern the growth and survival 
of transformed cells like cell cycle, NF-
κB, aggresome formation, stress 
pathways like SAPK/JNK etc.  The 
proteasomes affects cell-cycle 
progression by regulating cyclins, and 
can also increase or decrease apoptotic 
activity via caspases, Bcl-2, and NF-κB 
(9).  Proteasome inhibition can 
destabilize the regulation of CDC25A, 
CDC25C, KIP1 and the cyclins, which Reproduced from Adams, 2004 
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will make the cell more susceptible to apoptosis.  Because of the fact that cell cycle 
checkpoints in cancer cells are disrupted, the cells may be more heavily dependent on 
proteasome-mediated degradation of cell cycle regulators, both positive regulators like 
cyclins and negative regulators like p21 and p27, for their survival (15).  
The NF-κB family of transcription factors represents proteins bound to the 
inhibitor IκB, which while bound, remain inactive in the cytoplasm.  In response to 
cellular stress, the IκB inhibitor becomes deactivated by the proteasome, which results in 
NF-κB translocation into the nucleus and activates several pro-survival pathways (9).  
NF-κB has been shown to control cell proliferation by activating genes such as 
interleukin 2 (IL-2) and CD40 ligand, all of which are factors that promote proliferation 
of lymphoid and myeloid cells (25).  In addition, NF-κB has been shown to inhibit 
programmed cell death (25-29) by activation of genes known to block apoptosis via 
TNFα, as well as others (25,30).  The genes that are induced by NF-κB include cellular 
inhibitors of apoptosis, caspase-8/FADD, and members of the Bcl-2 family of proteins 
(25,30).  
 
Reproduced from Karin M, et al, 2002 
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NF-κB has also been shown to attenuate apoptotic responses to genotoxic 
anticancer drugs and ionizing radiation (25,29-31), and that inhibition of NF-κB pushes 
chemoresistant tumors toward apoptosis (31).  In addition to conferring resistance to 
cancer therapies, the anti-apoptotic activity of NF-κB can also have an important role in 
the emergence of neoplasms, by preventing the death of cells that have undergone 
chromosomal rearrangements or other types of DNA damage (25).  Diffuse large B-cell 
lymphomas that are of the activated B-cell (ABC) phenotype have elevated expression of 
NF-κB target genes, which encode cytokines, chemokines and anti-apoptotic proteins 
(25), and expression of a non-phosphorylateable IκB mutant (super-repressor) in these 
cells inhibits their proliferation (25).  In contrast, DLBCLs with a germinal-centre-like 
gene-expression profile seem to be resistant to the IκB super-repressor, which indicates 
that the canonical NF-κB signaling pathway, which depends on the IKKβ catalytic 
subunit and IκB degradation, is constitutively active in the activated B-cell-like DLBCL 
cells (25).     
Reactive oxygen species (ROS) generation can result in DNA damage as well as 
oxidation of fatty acids and proteins.  Eukaryotic cells continually produce ROS by 
electron transfer reactions, but ROS can be exacerbated by exogenous sources such as 
UV light, toxins, or drugs (32).  NF-kB is considered a primary oxidative stress-
responsive transcription factor that enhances the transcription of a variety of genes, 
including those for cytokines and growth factors, adhesion molecules, immunoreceptors, 
and acute response proteins (32).  Most if not all agents that activate NF-κB also trigger 
ROS formation  
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 It is well known that apoptosis requires a cascade of biochemical events, 
performed via a family of cysteine proteases called caspases (9).  Caspase-9 is the apical 
caspase, which directly activates caspases -3 and -7 through proteolytic cleavage (33).  
Active caspase-3 processes caspases -2 and -6, and activated caspase-6 activates caspases 
-8 and -10 (33).  Specifically, it is thought that caspase-8 and caspase-3 are the major 
effector caspases, essential for the apoptosis cascade (9,34).  Activation of caspase-2 is 
caused by cytotoxic stress, and is required for permeabilization of the mitochondria and 
the release of SMAC and cytochrome c (35).  Cytochrome c binds to Apaf-1 and 
activates caspase-9, which in turn, activates caspase-3 (35).  Caspase-4 on the ER is 
thought to play a role in ER stress-induced apoptosis (36).  Caspase precursors are 
constitutively expressed in the cell, and have to be activated via proteolytic cleavage by 
specific inducers.  Activation of NFκB can inactivate caspase-8 (9,37), therefore 
proteasome inhibition could prevent activation of the anti-apoptotic factor NF-κB, 
potentiate caspase activity, and induce apoptosis.   
 
PROTEASOME INHIBITORS 
Proteasome inhibitors might be natural or synthetic and five important classes of 
proteasome inhibitors exist: peptide aldehydes, peptide vinyl sulphones, peptide 
boronates, peptide epoxiketones and β-lactones (9).  The natural inhibitor lactacystin and 
synthetic peptide aldehydes were the first agents to be identified with the ability to inhibit 
proteasomes, yet they suffered from several limatations including poor stability and 
bioavailability, and lack of specificity (9,38).  Substituting the aldehyde with boronic acid 
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would enable the compound to achieve a covalent, reversible interaction with 
proteasomes, while achieving improved potency and selectivity. (9,38,39).  Bortezomib 
was one of the original 13 boronic-acid proteasome inhibitors selected for further study 
(9).  Studies have shown that the proteasome inhibitor bortezomib induced ROS 
formation, and played a critical role in caspase-9 activation in bortezomib-mediated 
apoptosis (40).   
 
BORTEZOMIB 
Bortezomib was originally synthesized in 1995 as MG-341 .It was developed by 
Millennium Pharmaceuticals. After promising preclinical results, the drug (PS-341) was 
tested in a small Phase I clinical trial on patients with multiple myeloma (MM) cancer.  
When one of the first volunteers to receive the drug in the clinical trial achieved a 
complete response, the drug was given priority at the company, and in 2003, bortezomib 
(Velcade) was approved for use in multiple myeloma by the FDA based on the results of 
the SUMMIT Phase II trial (38).    
Bortezomib is known to bind with 26S proteasome reversibly and cleared very 
rapidly from the plasma compartment; achieving 90% clearance within 15 minutes of 
intravenous administration (38). There is minimal intersubject and intrasubject variation 
in proteasome activity.  The effects of bortezomib are dose related, achieving 80% 
proteasome inhibition at a dose of approximately 1.96 mg/m
2
.  Monitoring the extent of 
20S proteasome inhibition in PBMCs collected from patients enrolled in Phase I clinical 
trials confirmed that levels of inhibition up to 80% did not cause excessive toxicity 
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(15,38,41-43).  Bioassay testing in rats indicated that most organs received a similar 
amount of drug, with no drug present in the testes, eyes, and central nervous system (38).  
Proteasome activity is restored 48 to 72 hours after cessation of bortezomib treatment 
(38).         
 
CARFILZOMIB (PR171) 
Carfilzomib is an epoxyketone that was developed by Proteolix, Inc. (South San 
Francisco, CA, USA) (15,44).  Carfilzomib differs from bortezomib in that it is a 
irreversible proteasome inhibitor, and it is more selective for the chymotryptic activity 
(15,44).  More importantly however is the fact that it can be given at a much more 
aggressive schedule, ie: doses that cause greater than 80% proteasome inhibition for at 
least 5 consecutive days (15,44).  Preclinical studies also indicate that PR171 is active 
against solid tumors as well as cell lines from patients resistant to bortezomib (Proteolix 
pipeline). Recent published result has indicated that carfilzomib is active against 
bortezomib resistant cells (45).    
        
 
HISTONE PROTEINS 
 Transcription in eukaryotic cells depends on the manner in which the DNA is 
packaged (46,47).  DNA is tightly compacted into the highly organized protein-DNA 
complex chromatin in resting cells to prevent access by transcription factors, thereby 
preventing replication.  The fundamental subunit of chromatin is called the nucleosome, 
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which is composed of an octamer of 4 core histones, for example a H3/H4 tetramer and 
two H2A/H2B dimers, surrounded by 146 bp of DNA, Fig. (46). During activation of 
transcription, this compact, inaccessible DNA is made available to replication proteins 
via nucleosome modification. (46,48).   
 
HISTONE DEACETYLASES 
 Histone tails are positively charged, due to the amine groups present on their 
lysine and arginine amino acids.  This allows the positively charged histone tails to 
interact with the negatively charged phosphate groups on the DNA backbone, keeping the 
DNA tightly compacted.  Acetylation partially neutralizes the positive charges of the 
histones, allowing for chromatin expansion and gene transcription (49).  This process 
involves the transfer of an acetyl group from the acetyl coenzyme A metabolic 
intermediary to the ε-amino group of lysine residues in histone tails, catalyzed by a group 
of enzymes known as histone acetyltransferases (HAT) (49).  Histone deacetylases 
remove these acetyl groups, thereby condensing the DNA and promoting transcriptional 
repression (49).     
 
HISTONE DEACETYLASE INHIBITORS (HDACi) 
Histone deacetylase inhibitors (HDACi) can elicit a range of responses that affect 
tumor growth and survival, including inhibition of cell cycle progression, induction of 
tumor cell-selective apoptosis, suppression of angiogenesis, and modulation of immune 
responses, as well as show promising activity against hematological malignancies in 
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clinical trials (50).  A major mechanism of apoptosis induction by HDAC inhibitors is 
through the induction of oxidative injury, or ROS formation (51).  HDAC inhibitors are 
considered to be among the most promising agents in drug development for cancer 
therapy (52-54), largely because it has been shown that these inhibitors present relatively 
low toxicity to normal cells, most likely due to the fact that normal cells are relatively 
resistant to HDACi-induced cell death, whereas a broad variety of transformed cells are 
sensitive to HDAC-induced cell death (52).  There are both natural and synthetic HDAC 
inhibitors, and they can be divided into several groups: hydroxamic acid derivatives, 
cyclic peptides, short-chain aliphatic acids, and benzamides (52).     
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Schematic representation of a nucleosome. Yellow represents the histones. Dark red 
depicts the histone tail that can be modi®ed to loosen DNA (purple) winding. The dark 
red circle represents a tail without an acetyl (Ac) group. The dark red ` banana shape ' 
represents a histone tail with an acetyl group, relieving the tight packaging of the DNA. 
(B) Transcriptional repression and activation in chromatin. Yellow circles represent core 
histone octamers ; in the upper panel, acetylated histone tails (dark red) are depicted 
emerging from the octamer (46).  Reproduced from de Ruijter, et al, 2003      
 
 
VORINOSTAT (SAHA) 
Vorinostat (SAHA, Zolinza) is a hydroxamic acid derived synthetic compound, 
and a pan-inhibitor of Class I and II HDACs (52,55).  It is the first HDAC inhibitor 
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approved for clinical use in cancer patients for treating cutaneous T-cell lymphoma by 
the US Food and Drug Administration.  It has
 
been shown to induce cell cycle arrest and 
apoptosis and prolong
 
survival in preclinical models of B-cell lymphoma (50,56), and 
Phase I trials are showing promising results (56-58).  It is likely necessary to use 
vorinostat in combination with other drugs for enhanced therapeutic effects (52).  
Already, HDACi have been shown to cooperate with radiation therapy, antitubulin 
agents, topoisomerase I and II inhibitors, cisplatin, the kinase inhibitor imanitib, 
proteasome inhibitors such as bortezomide, the heat shock protein-90 inhibitor 17-N-
allylamino-17-demethoxygeldanamycin, the Her2 receptor inhibitor trastuzumab, 
retinoids, inhibitors of DNA methylation, estrogen receptor antagonists, dexamethasone, 
and others (52).   
 
RATIONALE FOR COMBINING CARFILZOMIB AND VORINOSTAT 
Owing to the poor prognosis of DLBCL patients to bortezomib therapy, newer 
and more effective proteasome inhibitor was sought.  Development of second generation 
proteasome inhibitor i.e. carfilzomib was a step in this direction.  A combined drug 
regimen to potentiating the activity of carfilzomib will be an attractive option.  There are 
multiple reasons suggesting combination of carfilzomib and vorinostat may result in a 
synergistic interaction.  There is evidence that HDAC inhibitors activate the NF-κB 
survival pathways (59), whereas proteasome inhibitors block this activation (15). There is 
also evidence that proteasome inhibitors like bortezomib induce aggresome formation 
(60), which promotes cell survival, whereas HDAC inhibitors block the same (15,23,24).  
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In addition, both HDACI and proteasome inhibitors have been shown to induce ROS 
generation and oxidative stress (40,51).  Therefore, combining the two may result in a 
synergistic interaction. Bortezomib and vorinostat have also been shown to interact 
synergistically in many cancer cell types, including hematologic malignancies as well as 
solid tumors and under clinical trials.  In light of all this evidence we propose that 
combining carfilzomib and vorinostat will result in a synergistic interaction with respect 
to cell death in both GC and ABC DLBCL cell lines. 
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MATERIALS AND METHODS 
 
Cells 
SUDHL16 cells (GC subtype) was a kind gift from Dr. Alan Epstein, University 
of Southern California, LA. SUDHL4, SUDHL6 (both GC), OCI-LY10, OCI-LY3 (both 
ABC) were provided by Dr. Lisa Rimsza of University of Arizona, Tucson. Bortezomib-
resistant SUDHL16-10BR (GC) and SUDHL6-20BR (GC) were generated by exposing 
the respective parental cells to progressively increasing concentrations of bortezomib 
beginning with 1.0 nM. Once cells developed resistance to bortezomib, they were 
cultured in the absence of drug for two weeks prior to experiments. Multiple studies 
documented the persistence of drug resistance under these conditions.   SUDHL-10BR 
(GC) and Raji-20BR were generated by exposing the respective parental cells to 
progressively increasing concentrations of bortezomib beginning with 1.0 nM. Once cells 
developed resistance to bortezomib, they were cultured in the absence of drug for two 
weeks prior to experiments. Multiple studies documented the persistence of drug 
resistance under these conditions.  SUDHL16-sh-JNK cells were generated by 
electroporation (Amaxa, GmbH, Germany) using buffer L of a MAP8 shRNA 
(SuperArray Bioscience Corporation, Frederick, MD) into SUDHL16 parental cells 
according to the manufacturer’s instructions. Stable clones were selected by serial 
dilution using G418 as selection marker.  
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Cell Culture 
Cells were suspended in sterile plastic
 
T-flasks (Corning, NY) and placed in a 5% 
CO2, 37
0
C incubator.  Cells were counted on a Coulter Counter Cell and Particle Counter, 
and split when their counts were at least 9.0 x 10
5
 cells/mL, using RPMI media 
containing L-glutamine, pen-strep, non-essential amino acids, all provided by Invitrogen, 
and  sodium pyruvate and RPMI provided by Mediatech, Manassas, VA. All experiments 
were carried out within passage 6-24 to ensure uniformity of drug responses.   
 
Reagents 
 Carfilzomib (PR171 and PR-047) were provided by Proteolix, San Francisco, 
CA. Bortezomib (Velcade) was provided by Millennium Pharmaceuticals, Cambridge, 
MA. MnTBAP was provided by Calbiochem, CA.  N-Acetyl-L-cysteine was provided by 
Sigma-Aldrich, St. Louis, MO. 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein 
diacetate, acetyl ester (ROS dye) was provided by Molecular Probes, Eugene, OR.  7-
Aminoactinomycin D was provided by Sigma-Aldrich, St. Louis, MO. 
 
Experimental  Format 
Logarithmically growing cells were suspended in sterile plastic
 
T-flasks (Corning, 
NY), or sterile plastic cell culture plates (Greiner), in media containing 10% FBS 
(Atlanta Biologicals, Lawrenceville, GA). Cells were cultured at least 24 hours prior to 
treatment with designated
 
drugs. The flasks and plates were then placed in a 5% CO2, 
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37
0
C incubator for various intervals.  At the end of the incubation period,
 
cells were 
transferred to sterile centrifuge tubes, pelleted
 
by centrifugation at 400 x g for 10 min at 
room temperature,
 
and prepared for analysis as described below.
 
 All cells were tested 
regularly for mycoplasma contamination using the MycoAlert Mycoplasma Detection 
Kit, provided by Lonza, Inc., Rockland, ME, to insure that cells were free of mycolpasma 
prior to experimentation.  All experiments were performed using equivalent cell 
concentrations (e.g.,4.0-5.0 x 10
5
 cells/ml) to ensure conformity of drug responses.  
Assessment of cell death  
Drug effects on cell viability were monitored by flow cytometry using 7AAD as 
the staining dye.  Briefly, cells were stained with 25 μM 7AAD solution at room 
temperature in regular culture media and analyzed in the FL2 channel using the Becton 
Dickinson flow cytometer. Alternatively, cells were washed with 1x PBS and stained 
with Annexin V/PI (BD PharMingen, San Diego, CA) for 30min. at room temperature. 
Cells were then processed and analyzed using the cytofluorometer. Cells undergoing 
apoptosis were also periodically monitored by Annexin V staining to confirm 7AAD 
results. Cells were also analyzed for viability using the VIACOUNT reagent in 
conjunction with a GUAVA PCA instrument using CytoSoft software as per the 
manufacturer’s instructions. Results were verified by Trypan blue staining and 
enumeration of Trypan blue excluding cells using a hemocytometer. Results for each of 
these methods were found to be in good agreement. 
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Collection and processing of primary cells 
Primary DLBCL cells obtained with informed consent from the bone marrow of a patient 
with DLBCL and extensive marrow infiltration (>70%).  These studies have been 
approved by the Investigational Review Board of Virginia Commonwealth University. 
Bone marrow samples were collected in sterile syringes containing heparin and processed 
by standard techniques to separate mononuclear cells, after which CD34
+
 cells were 
isolated using an immunomagnetic bead separation technique as we have previously 
described in detail (61). CD34
+
 cells were then suspended in RPMI1640 medium 
containing 10% FCS and exposed to agents as described above for continuously cultured 
cell lines.  
 
Western blot Analysis  
Western blot samples were prepared from whole cell pellets. Equal amounts of 
protein (30µg) were separated by 4-12% Bis-Tris (Invitrogen) precast gel and probed 
with primary antibodies of interest as we have described in detail previously (61). The 
sources of primary antibodies were as follows: AIF, cytochrome c, p-JNK, JNK1,  p-
ERK, ERK,  Mcl-1, Bak, Bid, Bcl-xL, CD20, Bax, Bak, IREα, GRP94, GRP78, XBP, p-c-
Jun, c-Jun, NOXA, Bim and PUMA  were from Santa Cruz Biotechnology, Santa Cruz, 
CA.; cleaved caspase-8, cleaved caspase-3, p-p38, p38 ,  p-eIF2a,  eIF2a, CF Caspase 9 
were from Cell Signaling Technology, Beverly,
 
MA; Caspase7,  Caspase2, Mcl-1, XIAP  
were from BD Pharmingen (Transduction Laboratories), Lexington,
 
KY; PARP (C-2–
10), Smac was from Upstate Biotechnology, Lake Placid, NY; Caspase-8 was from 
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Alexis, San Diego, CA;  Tubulin was from Oncogene, San Diego, CA. Actin was 
purchased  from sigma, MO. Bcl-2 was from Dako, CA.  Caspase 4 was obtained from 
Stressgene Bioreagents, Ann, MI. Secondary antibodies were obtained from KPL Protein 
Research Products, Gaithersburg, MD, USA. 
 
ROS Generation Analysis 
Cells were suspended into 24-well cell culture plates for 24 hours.  Two hours 
prior to drug treatment, antioxidants MnTBAP or N-Acetyl-L-cysteine were added to the 
appropriate wells, and cells were collected, incubated with ROS dye for 20 mins in the 
dark at room temperature, and analyzed for ROS generation on the cytofluorometer 30 
minutes and 3 hours after drug treatment.   
 
Animal Studies 
Animal studies were performed in NIH-III nude mice procured from Charles 
River, Wilmington, MA, USA. 10x10
6 
SUDHL4 cells were pelleted by centrifugation, 
washed twice with 1X PBS and re-suspended in 75 ul of PBS. Cells were injected 
subcutaneously into the right flank. In order to improve the tumor take rate, cells were 
extracted from previously formed tumor (designated as SUDHLT cells) and grown for 
subsequent injection. Mice were checked two to three times a week for appearance of 
tumors.  Once the tumors were visible, mice were grouped having at least 3 to 4 tumors 
in each group with approximately equal mean tumor volume. Mice were treated with 
various concentrations of carfilzomib via tail vein injection twice a week (1
st
, 2
nd
, 8
th
, 9
th
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days etc) and vorinostat was administered by IP injection thrice a week (1
st
, 2
nd
, 3
rd
 , 8
th
, 
9
th, 
10
th
   days etc). Tumor volume was measured 2 to 3 times a week with the help of a 
caliper using the following formula  
  Tumor Volume (CC) =  Length (mm) X Width (mm)
2
 
                             2 
 
Mice were sacrificed once tumors were bigger than 2000 cc. Side effects of tumor 
growth and treatment was closely monitored by premature death of mice, loss of weight, 
and behavioral change such as lack of movement, etc.    
 
Formulation of carfilzomib and vorinostat for in vivo studies 
Vorinostat was originally dissolved in DMSO and stored in -80
0
C in small 
aliquots. Finally it is diluted in 1:1PEG400 and sterile water to have final composition of 
10% DMSO, 45% PEG400, 45% water. Volume of the treatment to each mouse with was 
restricted to 100ul or less. Stock carfilzomib was prepared with 10% sulfobutylether 
betacyclodextrin in 10mM citrate buffer pH 3.5 (vehicle) at the concentration 2mg/mL 
and stored at -80
0
C. Stocks carfilzomib solution was diluted with vehicle every day for 
treatment at various doses  
  
 
NF-κB Activity   
 
Nuclear protein was extracted using Nuclear Extract Kit (Active Motif) and NF-
κB activity was determined by using an enzyme linked immunosorbent assay (ELISA) 
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Kit TransAM NF-κB p65 Transcription Factor Assay Kit (Active Motif), according to 
manufacturer’s instructions. Briefly, the activated form of NF-κB that is present in 
nuclear extracts was detected by using an anti-p65 specific antibody that recognizes the 
NF-κB bound to a consensus DNA oligonucleotide immobilized in a 96-well plate. 
Addition of a secondary antibody conjugated to horseradish peroxidase provides sensitive 
readout by spectrophotometry. 
 
Cell Cycle Analysis 
Cells (4x10
6 
million/sample) were treated with varying drug concentrations, 
pelleted in 15 mL tubes, washed with PBS, and fixed in cold methanol and PBS at a ratio 
of 1 mL PBS to 3 mL methanol.  Cells were stored in -20 C at least for 24 hrs.  Cells 
were harvested for analysis and washed twice with ice cold PBS.  Cells subsequently 
stained by 500 ul of 50ug/ml propidium Iodide for 30 minutes and accrued by flow 
cytometry.  Individual cells population in each phage was determined with Modfit 
software.  
 
Collection of S-100 fraction  
Cells were harvested after drug treatment by centrifugation
 
at 600 x g for 10 min 
at 4°C.  Cell pellets were washed once with ice-cold PBS and resuspended in five 
volumes of buffer A [20 mM HEPES-KOH (pH 7.5), 10 mM KCl,
 
1.5 mM MgCl2, 1 mM 
sodium EDTA, 1 mM sodium EGTA, 1 mM DTT,
 
0.1 mM phenylmethylsulfonyl fluoride, 
and 250 mM sucrose]. After
 
being chilled for 30 min on ice, the cells were disrupted by
 
15 strokes of a glass homogenizer. The homogenate was centrifuged
 
twice to remove 
 24 
unbroken cells and nuclei (750 x g, 10 min, 4°C). S-100 fractions (supernatants) were 
then obtained
 
by centrifugation at 100,000 x g, 60 min at 4°C. All steps were performed 
on ice or 4°C.  
Statistical Analysis 
The significance of differences between experimental conditions
 
was determined 
using the two-tailed Student t test.
  
Characterization of synergistic and antagonistic 
interactions was performed using Median Dose Effect analysis in conjunction with a 
commercially available software program (CalcuSyn, Biosoft, Ferguson, MO). 
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RESULTS 
Proteasome inhibitors and HDAC inhibitors interact synergistically in a variety of   
DLBCL cell types 
 
Interactions between the proteasome inhibitor carfilzomib and HDAC inhibitors 
vorinostat and SBHA were assessed in SUDHL16 and SUDHL4 cells, which are both GC 
subtype, as well as OCI-Ly10 cells, which are the ABC subtype.  Individual exposures to 
low concentrations of carfilzomib and vorinostat for 16-24 hours induced limited lethality 
(e.g. 15-20% cell death).  Combined exposure for 16-24 hours however, resulted in a 
marked increase in cell death, e.g. ~70-75% (Figure 1A), with CI values less than 1.0 by 
Median Dose effect analysis denoting synergism (Figure 1B).   
To determine whether these findings are limited to carfilzomib and vorinostat, 
similar experiments were performed with SBHA, a commercially available HDAC 
inhibitor.  Our results indicate that interactions between proteasome inhibitors and HDAC 
inhibitors are not restricted to carfilzomib and vorinostat (Figure 1A).  Experiments 
performed with another HDAC inhibitor MS-275 resulted in similar synergistic 
interaction (data not shown).  Sequential treatment of SUDHL16 cells with carfilzomib 
and vorinostat resulted in response similar to that of simultaneous treatment regardless of 
which drug was treated first (Figure 1C).   
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Figure 1 Proteasome inhibitors and HDAC inhibitors interact synergistically in a variety of   DLBCL 
cells 
 
(A). SUDHL16, SUDHL4, and OCI Ly10 cells we treated with minimally toxic concentrations of 
carfilzomib ( 2-5nM) ± vorinostat (0.75-2.0uM), or SBHA (30-60uM) for 24-48 hrs, after which cell 
death was monitored by 7AAD/DiOC6 staining.  (B). Fractional Effect values were determined by 
comparing results to those of untreated controls, and Median Dose Effect analysis was employed to 
characterize the nature of the interaction. Combination Index (C.I.) values less than 1.0 denote a 
synergistic interaction.  (C). Sequential treatments were carried out in SUDHL16 cells, starting with 
pretreatment of either carfilzomib or vorinostat for 8hrs followed by the second drug for another 16 
hours after which cell death was monitored by 7AAD/DiOC6 staining. 
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Fig. 1A: Proteasome inhibitors and HDAC 
inhibitors interact synergistically in a variety of 
DLBCL cells 
 
 
 
 
 
 
Fig. 1B: Median dose effect analysis for 
SUDHL16 cells 
Fig. 1C: Sequential treatment with carfilzomib and 
vorinostat on SUDHL16 cells.  
 
co
nt
ca
rf
il 
- 1
.0
nM
vo
r 
- 1
.0
uM
ca
rf
il 
vo
r
co
nt
vo
r 
- 1
.0
uM
ca
rf
il 
- 3
.0
nM
vo
r 
 c
ar
fil
0
25
50
75
%
 C
el
l 
D
ea
th
 27 
Carfilzomib and vorinostat interact synergistically in DLBCL primary patient 
samples with minimal toxicity to normal cells 
 
Interactions between proteasome inhibitors and HDAC inhibitors were assessed in 
primary DLBCL patient samples collected from patients to verify whether our findings of 
synergistic interaction of carfilzomib and vorinostat can be re-capitulated in primary 
cells.  Individual exposure (10 hrs for samples presented in Figure 2A, 2B and 24 hrs for 
the sample presented in Figure 2C) to low concentrations of carfilzomib and vorinostat in 
ABC DLBCL cells (Figure 2A) induced limited lethality over control, while the 
combination produced a marked increase in lethality.  Similar results were obtained in 
DLBCL cells from a patient who was not pretreated with any agents (Figure 2B), as well 
as in GC DLBCL cells from a relapsed patient albeit with higher doses, (Figure 2C). To 
determine whether this drug combination is toxic to normal cells, CD34
+
 cells separated 
from bone marrow of a healthy donor were treated with 10 nM and 100 nM of 
carfilzomib and 1.5 µM of vorinostat.  Both 10 nM and 100 nM concentrations or 
carfilzomib, as well as 1.5 µM vorinostat were minimally toxic to normal cells.  Minimal 
toxicity was observed in cells treated with 10 nM carfilzomib and 1.5 µM vorinostat, and 
moderate toxicity was observed in cells treated with 100 nM carfilzomib and 1.5 µM 
vorinostat. However, no synergistic interaction was observed between these agents in 
these cells (Figure 2D).    
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Figure 2: Carfilzomib and vorinostat also interact synergistically in DLBCL primary patient samples  
 
(A-C) Primary cells obtained from patients as described in Methods and exposed to carfilzomib (2 - 
100nM) and Vorinostat (0.5 -1.0M) for 10 - 24 hrs.  The percentage of apoptotic cells was determined 
by Annexin V/PI staining and flow cytometry, and the percentage of viable cells in each sample was 
normalized to controls.  (D) Normal CD34
+
 cells were exposed to similar treatments.     
Fig. 2A 
Fig. 2C. 07-109-V015: Patient was previously 
treated with CD20 antibody and relapsed. The 
current phenotype is CD5+19+20-. The 
original diagnosis was consistent with germinal 
center. 
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Fig. 2D. Normal CD34
+
 cells were treated with 
10 nM and 100 nM carfilzomib and 1.5 µM 
vorinostat. 
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Combined exposure of DLBCL cells to carfilzomib and vorinostat induces 
mitochondrial injury, caspase activation in association with marked JNK activation 
and induction of DNA damage 
 
Treatment of SUDHL16 (a GC type DLBCL cells) for 14 hours with minimally 
toxic concentrations of carfilzomib and vorinostat resulted in a pronounced increase in 
activation of caspases-3, -8, -9 as well as release of mitochondrial pro-apoptotic proteins 
cytochrome c and SMAC (Figure 3A).  Similar results were obtained with other DLBCL 
lines (e.g. SUDHL4; data not shown).   
Effects of the combination were then examined in relation to MAPK signaling in 
SUDHL16 cells. While individual treatment of carfilzomib and vorinostat had little 
effect, combined treatment resulted in a dramatic increase in phosphorylation of the 
stress-related JNK kinase and that of its substrate c-Jun, as well as it’s upstream target 
SEK1 (Fig 3B).  In addition, carfilzomib alone induced p38 MAPK phosphorylation, but 
this was marginally enhanced by vorinostat (Figure 3B).   
In view of evidence linking proteasome inhibitor lethality and induction of ER 
stress (54), effects of the combination were examined with respect to several ER stress 
markers. Whereas individual exposure exerted minimal effects, combined treatment 
resulted in modest but discernible increase in caspase-2 and a significant increase in 
caspase-4 cleavage/activation(Figure 3A).  However we have also investigated the effect 
of carfilzomib and vorinostat on other ER related targets such as eIF2 phosphorylation, 
ATF4, PERK, etc which are considered to be the hallmark of ER stress induction, but we 
have not observed any major changes (data not shown).   
 30 
There is a marked increase in the DNA damage marker γH2AX (Figure 3C).  
Also, we observe a notable decrease in the phosphorylation of AKT, as well as an 
increase in p21 and SOD2.  Interestingly, this combination induced a marked increase in 
ERK phosphorylation (Figure 3D).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3A 
Fig. 3B 
Fig. 3D Fig. 3C 
Figure 3: Effects of carfilzomib and vorinostat on expression of relevant target proteins 
 
Cells were treated with minimally toxic concentrations of carfilzomib (2-5 nM) ± vorinostat (0.75-2.0 
uM) for 24-48 hrs.  After treatment cells were lysed, protein denatured, and subjected to Western blot 
analysis with the indicated primary antibodies.  Blots were then stripped and reprobed with anti-actin 
or anti-tubulin to ensure equal loading and transfer of protein (20 μg in each lane).  (A) markers of 
apoptosis, (B) MAPK pro-apoptotic pathway, (C) DNA damage markers, (D) other relevant targets. 
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Combined treatment of carfilzomib and vorinostat blocks the vorinostat induced 
activation of NF-κB. 
 
It was previously reported that proteasome inhibitor bortezomib blocks the HDAC 
inhibitors induced Nf-κB activation which may be responsible, at least partly for their 
synergistic interaction. To whether similar phenomenon also involved in the interaction 
of carfilzomib and vorinostat, we treated SUDHL4 cells with minimally toxic 
concentrations of carfilzomib and vorinostat produced a significant decrease in NF-κB 
activity.  Vorinostat alone resulted in a pronounced increase of NF-κB activity, which 
was significantly reduced in combination (Figure 4A).  As expected, increasing the 
concentration of carfilzomib decreased NF-κB activity (Figure 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4A. Co-administration of carfilzomib and 
vorinostat decreases NF-κB activity in SUDHL4 
cells 
Fig. 4B. Increasing carfilzomib concentration 
decreases NF-κB activity in SUDHL4 cells. 
Figure 4: Effects of carfilzomib and vorinostat on NF-κB activity in SUDHL4 cells 
 
Nuclear protein was extracted using Nuclear Extract Kit (Active Motif) and NF-κB activity was 
determined by using an enzyme linked immunosorbent assay (ELISA) Kit TransAM NF-κB p65 
Transcription Factor Assay Kit (Active Motif), as described in Methods.  (A) Vorinostat alone 
increases NF-κB activity, which is subsequently blocked by co-administration of carfilzomib.  (B) 
Increasing concentrations of carfilzomib alone decreases NF-κB activity. 
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Enhanced JNK activation plays a significant functional role in 
carfilzomib/vorinostat lethality in DLBCL cells. 
 
To gain insights into the functional role of JNK activation in lethality of 
carfilzomib and vorinostat a genetic approach was employed. ShRNA knockdown of 
JNK1 (Figure 5A) in SUDHL 16 cells significantly diminished carfilzomib/vorinostat-
mediated apoptosis (Fig 5B). It is consistent with other published results and suggests 
that JNK activation plays a functional role in the activity of this drug regimen.  
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Figure 5: Enhanced JNK activation plays a significant functional role in carfilzomib/vorinostat 
lethality in DLBCL cells 
 
SUDHL16 cells were stably transfected with JNK shRNA or vectors encoding a scrambled sequence 
were exposed to 3.0 nM carfilzomib and 0.75 µM vorinostat. After 24 hr of drug exposure, apoptotic 
cells were monitored by 7AAD and DiOC6 staining and flow cytometry.  (A) Effect of JNK1 
knockdown on carfilzomib/vorinostat lethality.  (B) Western blot showing extent of JNK1 suppression.  
For (B) ** sigmificantly lower than values for empty vector controls; p < 0.05    
Fig. 5B. Downregulation of JNK1 by shJNK significantly 
decreases apoptosis in SUDHL16 cells. 
Fig. 5A. Western blot showing 
extent of JNK1 downregulation 
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Carfilzomib and vorinostat induced synergistic lethality involves ROS generation in 
SUDHL16 cells 
 
Since proteasome inhibitor and HDAC inhibitors are known to induce oxidative 
stress (62,63), we further studied whether combined treatment of carfilzomib and 
vorinostat can further induce ROS generation when treated with sub-lethal concentration. 
Exposure of SUDHL16 cells (3 hr) to 3.0 nM carfilzomib and 0.75 µM vorinostat 
resulted in a marked increase in ROS generation, which was significantly reduced by co-
administration of the antioxidant MnTBAP (Figure 6A).  Co-administration of the 
antioxidant MnTBAP resulted in a significant decrease in cell death (Figure 6B).  Co-
administration with MnTBAP also significantly reduced caspase-3 activation as well as 
JNK phosphorylation (Figure 6C), both indicative of reduced cell death.     
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Figure 6:  Carfilzomib/vorinostat lethality involves ROS generation in DLBCL cells 
 
(A) SUDHL16 cells (preteated with or without 5 mM MnTBAP for 3 hrs) were exposed to 3.0 nM 
carfilzomib ± 0.75 µM vorinostat for 4 hrs. At the end of the drug exposure, ROS generation was 
monitored via flow cytometry as described in Methods.  (B) SUDHL16 cells (preteated with or without 
75 mM MnTBAP for 3 hrs) were exposed to 3.0 nM carfilzomib ± 0.75 µM vorinostat for 24 hrs. At 
the end of the drug exposure, cell death was monitored by 7AAD/DiOC6 staining as described in 
Methods.  (C)  SUDHL16 cells (preteated with or without 75 mM MnTBAP for 3 hrs) were exposed to 
3.0 nM carfilzomib ± 0.75 µM vorinostat for 24 hrs. At the end of the drug exposure, cells were 
harvested, lysed, protein denatured, and subjected to Western blot analysis with the indicated primary 
antibodies.      
 
C
on
t
C
ar
fil
V
or
T
B
A
P
C
ar
fil
+V
or
T
B
A
P+
C
ar
fil
+V
or
0
10
20
30
40 Cont
Carfil
Vor
TBAP
Carfil+Vor
TBAP+Carfil+Vor
%
 R
O
S
 g
en
er
a
ti
o
n
Fig. 6A. Incubation with MnTBAP for 3 hrs 
prior to treatment significantly reduces ROS 
generation. 
Fig. 6B.  Blocking ROS generation significantly 
reduces cell death.   
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Co-administration of carfilzomib and vorinostat causes cell cycle arrest in the G2-M 
phase in both GC and ABC DLBCL subtypes 
 
To gain insight into whether or not this drug combination causes cell cycle arrest, we 
analyzed the cell cycle in both GC and ABC subtypes.  Single treatments with minimally 
toxic concentrations of carfilzomib (7.5 nM) and vorinostat (1.5 µM) in OCI-Ly10 ABC 
type DLBCL cells resulted in minimal cell cycle arrest in the G2-M phase, while 
combinational treatments resulted in a marked increase in G2-M arrest (Figure 7A).  
Parallel experiment was carried out in SUDHL4 cells, which are of the GC subtype, and 
while minimally toxic concentrations of carfilzomib (5.0 nM) and vorinostat (1.5 µM) 
resulted in minimal G2-M arrest, combination therapy resulted in a very large increase in 
G2-M arrested cells (Figure 7B).     
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Figure 7: Co-administration of carfilzomib and vorinostat results in G2-M cell cycle arrest in both ABC and GC DLBCL subtypes.   
 
OCI Ly10 and SUDHL4 cells were treated with carfilzomib and vorinostat as indicated.  After treatment, cells were collected, 
fixed in ice cold methanol at a ratio of 1 mL PBS to 3 mL methanol, and analyzed by flow cytometry as described in Methods.  (A) 
OCI Ly10.  (B) SUDHL4. 
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Fig. 7A.  Co-administration of carfilzomib and vorinostat 
in OCI Ly10 cells results in marked G2-M arrest    
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Fig. 7B. Co-administration of carfilzomib and vorinostat 
in SUDHL4 cells results in striking G2-M arrest    
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There is minimal cross-resistance to carfilzomib in bortezomib resistant DLBCL 
lymphoma cells, and is overcome by a synergistic combined treatment of carfilzomib 
and vorinostat. 
 
Since patients treated with bortezomib often relapse and become resistant to their 
treatment, we examined whether or not there is cross resistance to carfilzomib in 
bortezomib resistant DLBCL cells. To determine whether similar interactions might 
occur in cells resistant to bortezomib, SUDHL16 and Raji cells that had been adapted to 
grow in the presence of bortezomib were employed. These cells (e.g. SUDHL16-10BR, 
Raji-20BR) were maintained in the presence of 10nM and 20nM of bortezomib 
respectively without any impact on cell growth or viability. These cells express 
equivalent CD20 expression, compared to their parental counterparts, confirming their B-
cell origin (64). To rule out the possibility that bortezomib resistance might reflect 
development of the multi-drug resistance (MDR) phenotype, Pgp expression was 
monitored by flow cytometry.  No increase in Pgp expression was observed in either 
resistant cell line, nor did cross-resistance to VP-16, a Pgp substrate, occur (data not 
shown).  
Both Raji-20BR and SUDHL16-10BR cells exhibited minimal cross resistance to 
carfilzomib (Figure 8A-B).  This cross-resistance is easily overcome via combinational 
treatments using minimally toxic concentrations of carfilzomib (5-15 nM) as well as 
vorinostat (1.5-2.0 μM)  and SBHA (40-60 μM) in both SUDHL16-10BR and Raji-20BR 
cell lines, as combined exposure for 16-24 hours resulted in a marked increase in cell 
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death, e.g. ~65-75% (Figure 8C).  CI values less than 1.0 by Median Dose effect analysis 
denoting synergism (Figure 8D).   
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Figure 8: Minimal cross-resistance to carfilzomib was observed in bortezomib resistant DLBCL 
lymphoma cells, and is overcome by co-administration of carfilzomib and vorinostat. 
 
(A-B) Raji-20BR and SUDHL16-10BR were treated with increasing concentrations of carfilzomib as 
indicated, and cell death was monitored by 7AAD/DiOC6 staining.  (C) SUDHL16-10BR and Raji-
20BR cells were treated with minimally toxic concentrations of carfilzomib (5-15nM) ± vorinostat 
(1.5-2.0μM), or SBHA (40-60μM) for 24-48 hrs, after which cell death was monitored by 
7AAD/DiOC6 staining.  (D) Fractional Effect values were determined by comparing results to those of 
untreated controls, and Median Dose Effect analysis was employed to characterize the nature of the 
interaction. Combination Index (C.I.) values less than 1.0 denote a synergistic interaction.     
 
Fig. 8A. Marginal cross-resistance to 
carfilzomib is observed in Raji cells resistant 
to 20nM bortezomib.   
Fig. 8B. Marginal cross-resistance to 
carfilzomib is observed in SUDHL16 cells 
resistant to 20nM bortezomib.   
Fig. 8C. Bortezomib-induced cross-resistance 
to carfilzomib is overcome in both Raji-20BR 
and SUDHL16-10BR  
Fig. 8D. Combination index values less than 
1.0 indicate synergy 
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Co-administration of carfilzomib and vorinostat induce in vivo tumor growth 
reduction in SUDHL4T cells 
 
We have further investigated the antitumor activity of carfilzomib and vorinostat 
in BNX mice (NIH-III) bearing
 
established human tumor xenografts derived from 
SUDHL4T cells as described in methods. First we have evaluated the antitumor effect of 
carfilzomib and vorinostat alone against this SUDHL4T tumor cells.  Carfilzomib was 
administered in doses of 0.5 mg/Kg, 2.0 mg/Kg, and 3.0 mg/Kg and we have observed 
dose dependent reduction of tumor growth starting with 2.0 mg/Kg (Figure (9A & 9B). 
We have also observed that treatment with vorinostat (75 mg/Kg) also induced significant 
tumor growth reduction (Figure 9C). Based on the results of single drug response of 
carfilzomib and vorinostat, we have performed two separate set of experiments with the 
following dosing 
  Experiment -1         carfilzomib – 1.5 mg/kg & vorinostat – 40 mg/kg 
  Experiment -2         carfilzomib – 3.0 mg/kg & vorinostat – 60 mg/kg 
Each group of the experiment has four groups of mice, with each group having 3-4 mice 
treated. One group of mice was treated with vehicle, where as two groups were treated 
with either carfilzomib or vorinostat alone and remaining groups was treated with 
combined dose of carfilzomib and vorinostat.  Based on the results of four weeks of 
dosing, we have observed that co-treatment of carfilzomib and vorinostat have induced 
significantly more growth reduction of tumors in comparison to the single drug treatment 
(Figure 9D & 9E). However we have not observed any tumor regression in any of the 
mice.     
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Fig. 9A.  Photographs taken of mice treated with increasing doses of carfilzomib  
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Fig. 9B. Tumor volumes in mice treated with 
increasing concentrations of carfilzomib.  
Fig. 9C. Tumor volumes in mice treated with  
75 mg/Kg of vorinostat  
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Figure 9: Carfilzomib and vorinostat cause tumor growth reduction in SUDHL4T cells 
 
NIH-III nude mice were treated with carfilzomib ± vorinostat as previously described in Methods, at 
the indicated concentrations.  (A) Photographs of single treatments with carfilzomib.  (B-C) Tumor 
volumes after single treatments with carfilzomib and vorinostat at the indicated concentrations.  (D-E) 
Tumor volumes after co-administration of carfilzomib and vorinostat as described in Methods, at the 
indicated concentrations.  For (A) & (B) * = significantly grater than values for carfilzomib and 
vorinostat treatment alone; p < 0.05         
  
Fig. 9E. Tumor volumes in mice treated with 
3.0 mg/Kg carfilzomib and 60 mg/Kg 
vorinostat  
Fig. 9D. Tumor volumes in mice treated with 
1.5 mg/Kg carfilzomib and 40 mg/Kg 
vorinostat  
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DISCUSSION 
 Since recent reports of clinical trials of Bortezomib in diffuse large b-cell 
lymphoma patients have demonstrated poor clinical response (3,65), development of 
alternative therapeutic options based on new generation of proteasome inhibitors may be 
an attractive choice. Second generation of proteasome inhibitors, i.e. carfilzomib which 
has been reported to have improved efficacy to bortezomib, can logically be used to 
develop a drug regimen to treat DLBCL patients. 
 
 The present evidence extends previous findings that HDAC inhibitors activate the 
NF-κB survival pathways (59), whereas proteasome inhibitors block this activation (15).  
Bortezomib and vorinostat have also been shown to interact synergistically in many 
cancer cell types, including hematologic malignancies as well as solid tumors, and this 
study extends these finding to the second generation proteasome inhibitor carfilzomib 
and DLBCL cells.  There is clear synergy in combinations of carfilzomib and vorinostat 
in diffuse large B-cell lymphoma cell lines and patient samples.  Several mechanisms 
appear to be playing a role in this combined lethality, including mitochondrial outer 
membrane permeabilization, caspase activation, ROS generation, and cell cycle arrest.   
  
 Recently, microarray analyses performed on untreated DLBCL has lead to the 
identification of two main sub-types, germinal center (GC-DLBCL), and activated B-cell 
(ABC-DLBCL).  Both have a distinct gene expression profile, characteristic of either 
normal germinal center b-cells or activated blood memory B-cells (4).  The germinal 
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center-like subgroup is correlated with a significantly better prognosis in comparison 
with the activated B-cell like subgroup (4), and the 5-year survival rate of both is 59% 
and 30% respectively (5).  A third subgroup is comprised of cases that do not express the 
genetic profile of either the ABC or GC subgroups (4) was not the subject of this study.  
Synergistic interactions with carfilzomib and vorinostat on cell death were observed in 
both GC and ABC DLBCL cells, and similar results were obtained with other HDAC 
inhibitors such as SBHA and MS-275.  Therefore these results are applicable to other 
classes of HDAC inhibitors, and are not restricted to vorinostat alone.  Combination-
induced cell death did not appear to depend on whether the treatment was sequential or 
consecutive, as the results for both studies were very similar.  Similar synergistic 
interactions were also observed in both the ABC and GC subgroups of patient samples, 
including samples from relapsed patients.   
For any cancer treatment regimen to be viable and effective, it must not be overly 
toxic to normal cells.   It is important to note that no synergistic interaction with the two 
compounds was observed in CD34
+
 normals, indicating that this treatment regimen 
presents minimal toxicity to untransformed cells.  
 
 The stress-related MAPK JNK is known to exert a pro-apoptotic role in cellular 
responses to diverse noxious stimuli (66).  JNK activation has been implicated in 
proteasome inhibitor lethality in both hematopoietic (40,61) and non-hematopoietic 
malignant cells (67).  Our results show significant phosphorylation of JNK, as well as 
phosphorylation of its upstream target SEK1 and its downstream target c-Jun.  To 
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confirm the functional role of JNK in the combinational regimen of carfilzomib and 
vorinostat, a genetic shRNA knockdown of JNK was employed.  This approach resulted 
in a significant reduction in cell death, as well as caspase-3 activation and JNK 
phosphorylation (data not shown), indicating that the JNK MAPK pathway is playing a 
role in carfilzomib and vorinostat combination induced apoptosis.   
To determine the effect of the combination regimen on various relevant target 
proteins, we performed western analyses on whole cell lysates.  Our data shows 
significant pro-apoptotic caspase activation, marked increase in the oxidative stress 
marker SOD2, marked decrease in AKT, and marked increase of the DNA damage 
marker γH2AX.  Interestingly, there was a large increase in ERK (p44/42) 
phosphorylation, indicating that the pro-survival pathway is being activated even in 
combination.   
 In light of evidence that proteasome inhibitors and HDAC inhibitors both induce 
ROS generation and oxidative stress (40,51), we looked to see whether this event plays a 
role in apoptosis as a result of combinational treatment with the two compounds.  Single 
treatments of SUDHL16 cells with either carfilzomib or vorinostat resulted in a moderate 
increase in ROS generation, however combining the two compounds resulted in a very 
profound ROS increase as well as cell death.  Co-administration of the MnTBAP 
antioxidant with carfilzomib and vorinostat significantly blocked ROS generation and 
resulted in a significant reduction of cell death.  In addition, co-administration of 
MnTBAP together with carfilzomib and vorinostat resulted in a marked decrease in the 
activation of the apoptotic effecter caspase-3, a phenomenon known to play an important 
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role in mediating the
 
cellular response to oxidative injury (51,68).  A profound reduction 
in the phosphorylation of JNK, part of the stress-related pro-apoptotic pathway (66) was 
also observed in the combined regimen of carfilzomib and vorinostat.  Finally, NF-κB is 
known to play a major protective role in cells undergoing oxidative damage (32), thus the 
carfilzomib/vorinostat regimen may trigger cell death through multiple mechanisms, 
including ROS generation as well as a reduction in NF-κB activation.  These results 
provide support for the notion that
 
disruption of the cellular redox state may represent an 
important
 
mechanism underlying DLBCL cell death when exposed to these compounds, 
both alone and in combination.    
Combined exposure of both GC and ABC DLBCL cells was associated with cell 
cycle perturbation.  Minimally toxic concentrations of vorinostat alone had little effect on 
cell cycle arrest, while carfilzomib alone resulted in a slight increase  cells population in 
G2-M phase.  Combined treatments however resulted in profound increases of G2-M 
arrested cells.  This evidence suggests that cell cycle arrest from a regimen combining 
carfilzomib and vorinostat may play a role carfilzomib and vorinostat mediated cell 
death. This is very much in accord with our finding that combined treatment of 
carfilzomib and vorinostat induces DNA damage as evident from the up regulation of 
γH2AX          
 The NF-κB pathway is known to play a crucial role in DLBCL cell survival (9), 
and the capacity of carfilzomib to inhibit the NF-κB pathway by blocking protesomal IκB 
degradation likely plays a key role in the activity of this agent against DLBCL cells.  In 
accordance with this evidence, our findings show that increasing concentrations of 
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carfilzomib block activation of NF-κB.  In accordance with evidence that HDAC 
inhibitors induce NF-κB activation (59), our studies show a profound increase in NF-κB 
activation in vorinostat-treated cells.  Combined exposure of SUDHL4 cells to 
carfilzomib and vorinostat was associated in a very substantial decline in NF-κB activaty.  
These findings demonstrate a potential pathway for the synergy of carfilzomib and 
vorinostat.   
 Acquired resistance to treatment is always a concern in patients currently 
undergoing therapy, especially if the patient has relapsed.  To address this concern, we 
examined whether or not there is cross resistance to carfilzomib in bortezomib resistant 
DLBCL cells.  We generated SUDHL16 cells resistant to 10 nM bortezomib (SUDHL16-
10BR), and Raji cells resistant to 20 nM bortezomib (Raji-20BR), with both lines having 
an 4-5 fold increase of LC50 than the parental cells.  Both SUDHL16-10BR and Raji-
20BR cells exhibited partial cross resistance to carfilzomib.   Upon treatment of the 
resistant lines with a combined regimen of carfilzomib and vorinostat, we saw a profound 
synergistic response in both resistant cell lines, indicating that this combination regiment 
can be an attractive option in patients that developed resistant to other proteasome 
inhibitors.   
 In vivo studies are crucial to confirm the efficacy of this drug combination 
regimen.  Our early in vivo studies were performed with single drug dosing by injecting 
NIH-III beige nude mice subcutaneously with SUDHL4 cells passaged from extracted 
tumors that developed in athymic nude mice, in order to determine the dose-response.  
These passaged cells were given the SUDHL4T designation.  Our results indicated that 
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increasing concentrations of carfilzomib had a marked effect on the growth rate of 
SUDHL4T tumors, and a 75 mg/kg dose of vorinostat had a profound effect on tumor 
growth.  Two experiments with combining carfilzomib and vorinostat were performed: 
the first used 1.5 mg/kg of carfilzomib and 40 mg/kg of vorinostat and the second used 
3.0 mg/kg of carfilzomib and 60 mg/kg of vorinostat.  Both combinations resulted in a 
decrease in tumor volume when compared to single drug treatments and the control, with 
the higher dose resulting in a slightly better effect.  However, we have not seen any tumor 
regression in any of the experiments.  These findings may suggest that animals should be 
treated for longer period of time, treatments should be performed more frequently, or the 
concentrations of drugs should be optimized further. Since we also observed a large 
increase in ERK phosphorylation induced by the combination of carfilzomib and 
vorinostat in vitro, it may be worthwhile to combine carfilzomib and vorinostat with a 
MEK inhibitor such as PD184352.  It will also be interesting to see if we can improve the 
in-vivo efficiency by sequentially scheduling the drug treatment rather than administering 
the agents simultaneously.    
 
 In conclusion, our evidence supports the notion that combining the second-
generation proteasome inhibitor carfilzomib with the HDAC inhibitor vorinostat presents 
a viable treatment option for both germinal center and activated B-cell type DLBCL.  
Cell death is mediated by various mechanisms, including ROS generation, cell cycle 
arrest, JNK activation, induction of DNA damage, and NF-κB inhibition.  This regimen is 
effective in both cell lines as well as patient samples, and is able to overcome any cross 
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resistance to the first-generation proteasome inhibitor bortezomib.  Finally, this 
combination shows promising results in vivo and requires further investigation for 
clinical development.   
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